These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 23054338)

  • 1. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis.
    Abarbanel DN; Seki SM; Davies Y; Marlen N; Benavides JA; Cox K; Nadeau KC; Cox KL
    J Clin Immunol; 2013 Feb; 33(2):397-406. PubMed ID: 23054338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis.
    Ali AH; Damman J; Shah SB; Davies Y; Hurwitz M; Stephen M; Lemos LM; Carey EJ; Lindor KD; Buness CW; Alrabadi L; Berquist WE; Cox KL
    Scand J Gastroenterol; 2020 Aug; 55(8):941-950. PubMed ID: 32633158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic.
    Davies YK; Cox KM; Abdullah BA; Safta A; Terry AB; Cox KL
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):61-7. PubMed ID: 18607270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective function of sclerosing cholangitis on IBD.
    Bedke T; Stumme F; Tomczak M; Steglich B; Jia R; Bohmann S; Wittek A; Kempski J; Göke E; Böttcher M; Reher D; Franke A; Lennartz M; Clauditz T; Sauter G; Fründt T; Weidemann S; Tiegs G; Schramm C; Gagliani N; Pelczar P; Huber S
    Gut; 2024 Jul; 73(8):1292-1301. PubMed ID: 38839272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis.
    de Krijger M; Wildenberg ME; de Jonge WJ; Ponsioen CY
    J Hepatol; 2019 Sep; 71(3):603-615. PubMed ID: 31108158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver enzyme elevations within 3 months of diagnosis of inflammatory bowel disease and likelihood of liver disease.
    Goyal A; Hyams JS; Lerer T; Leleiko NS; Otley AR; Griffiths AM; Rosh JR; Cabrera JM; Oliva-Hemker MM; Mack DR; Rick JN; Pfefferkorn MD; Carvalho R; Grossman AB; Hitch MC; Sudel B; Kappelman MD; Saeed SA; Faubion WA; Schaefer ME; Markowitz JF; Keljo DJ;
    J Pediatr Gastroenterol Nutr; 2014 Sep; 59(3):321-3. PubMed ID: 24796799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.
    Ricciuto A; Liu K; El-Matary W; Amin M; Amir AZ; Aumar M; Auth M; Di Guglielmo MD; Druve Tavares Fagundes E; Rodrigues Ferreira A; Furuya KN; Gupta N; Guthery S; Horslen SP; Jensen K; Kamath BM; Kerkar N; Koot BGP; Laborda TJ; Lee CK; Loomes KM; Mack C; Martinez M; Montano-Loza A; Ovchinsky N; Papadopoulou A; Perito ER; Sathya P; Schwarz KB; Shah U; Shteyer E; Soufi N; Stevens JP; Taylor A; Tessier ME; Valentino P; Woynarowski M; Deneau M;
    Aliment Pharmacol Ther; 2024 May; 59(10):1236-1247. PubMed ID: 38462727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
    Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms.
    Sebode M; Peiseler M; Franke B; Schwinge D; Schoknecht T; Wortmann F; Quaas A; Petersen BS; Ellinghaus E; Baron U; Olek S; Wiegard C; Weiler-Normann C; Lohse AW; Herkel J; Schramm C
    J Hepatol; 2014 May; 60(5):1010-6. PubMed ID: 24412607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term oral vancomycin for refractory inflammatory bowel diseases without Clostridium difficile infection: Lessons from primary sclerosing cholangitis.
    Du W; Han W; Dong J
    Med Hypotheses; 2020 Nov; 144():110211. PubMed ID: 33254520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving Practice and Changing Phenotype in Pediatric Autoimmune Liver Disease: Outcomes From an Australian Center.
    Singh H; Balouch F; Noble C; Lewindon P
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):80-85. PubMed ID: 29470284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease.
    Henriksen EK; Jørgensen KK; Kaveh F; Holm K; Hamm D; Olweus J; Melum E; Chung BK; Eide TJ; Lundin KE; Boberg KM; Karlsen TH; Hirschfield GM; Liaskou E
    J Hepatol; 2017 Jan; 66(1):116-122. PubMed ID: 27647428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease.
    Hadley T; Gillespie S; Espinoza H; Prince J; Gronbaek H; Chandrakasan S; Kuguthasan S; Kolachala VL; Gupta NA
    Autoimmunity; 2020 Aug; 53(5):253-260. PubMed ID: 32370568
    [No Abstract]   [Full Text] [Related]  

  • 14. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease.
    Sayed A; Assis DN; Silveira MG; Deng Y; Ciarleglio M; Gaidos JKJ; Proctor DD; Al-Bawardy B
    Eur J Gastroenterol Hepatol; 2023 Mar; 35(3):270-274. PubMed ID: 36708297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigative MRI cholangiopancreatography for primary sclerosing cholangitis-type lesions in children with IBD.
    Alexopoulou E; Xenophontos PE; Economopoulos N; Spyridopoulos TN; Papakonstantinou O; Panayotou I; Dimakou K; Roma E; Kelekis NL
    J Pediatr Gastroenterol Nutr; 2012 Sep; 55(3):308-13. PubMed ID: 22569526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis.
    Damman JL; Rodriguez EA; Ali AH; Buness CW; Cox KL; Carey EJ; Lindor KD
    Aliment Pharmacol Ther; 2018 Apr; 47(7):886-895. PubMed ID: 29411404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease.
    Belle A; Laurent V; Pouillon L; Baumann C; Orry X; Lopez A; Rousseau H; Bronowicki JP; Peyrin-Biroulet L
    Dig Liver Dis; 2018 Oct; 50(10):1012-1018. PubMed ID: 30076016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vedolizumab Therapy in Children With Primary Sclerosing Cholangitis: Data From the Pediatric Primary Sclerosing Cholangitis Consortium.
    Laborda TJ; Ricciuto A; Aumar M; Carman N; DiGuglielmo M; Draijer LG; Furuya KN; Gupta N; Koot BGP; Loomes KM; Lytvyak E; Martinez M; Miloh T; Montano-Loza AJ; Perito ER; Sathya P; Shah U; Shteyer E; Singh R; Taylor A; Valentino PL; Vitola B; Zerofsky M; Zizzo A; Deneau MR
    J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):459-464. PubMed ID: 32740528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiome in primary sclerosing cholangitis: A review.
    Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
    World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children.
    Gilger MA; Gann ME; Opekun AR; Gleason WA
    J Pediatr Gastroenterol Nutr; 2000 Aug; 31(2):136-41. PubMed ID: 10941964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.